Talphera, Inc.
NCM: TLPHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Talphera, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TLPH Z-Score →About Talphera, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.
📊 Fundamental Analysis
Talphera, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -114.7%, which indicates that capital utilization is currently under pressure.
At a current price of $0.76, TLPH currently sits at the 32nd percentile of its 52-week range (Range: $0.38 - $1.57).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$38.07M
Trailing P/E
--
Forward P/E
-2.72
Beta (5Y)
0.56
52W High
$1.57
52W Low
$0.38
Avg Volume
205K
Day High
Day Low